We describe a case of a 37-year-old woman with a left axillary mass. Often, the initial differential diagnosis of an axillary mass is not easy to make. We performed fine-needle aspiration of the axillary mass that revealed the presence of numerous epithelial neoplastic cells. A bilateral digital mammography, chest and abdomen computed tomography scan, and a magnetic resonance imaging scan (MRI) of the axillary region were performed. In our case, the MRI was able to exclude the presence of neoplastic tissue in the breast; moreover, it confirmed the presence of metastatic lymph nodes and recognized a second type of nodular lesion in the axilla, showing on the MRI a radiologic pattern similar to breast tissue.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3816/CBC.2008.n.021 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
First-line combination therapy of immunotherapy plus anti-angiogenic drug for thoracic SMARCA4-deficient undifferentiated tumors in AIDS: a case report and review of the literature.
Front Immunol
January 2025
Department of Respiratory Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Background: Thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UT) exhibit a notably aggressive phenotype, which is associated with poor patient survival outcomes. These tumors are generally resistant to conventional cytotoxic chemotherapy, thereby limiting the availability of effective treatment options.
Case Presentation: We describe a 69-year-old AIDS patient who initially presented with a fused, enlarged lymph node on the right clavicle and mild, unexplained pain under the right axilla that worsened with severe coughing episodes.
ACTB::ZMIZ2-rearranged adnexal carcinoma: a second case.
Virchows Arch
January 2025
Department of Pathology, Université de Tours, Centre Hospitalier Universitaire de Tours, 37044, Tours, France.
A case of cutaneous adnexal neoplasm with unusual squamoid morphology and harboring an in frame ACTB::ZMIZ2 fusion transcript was recently described. Herein, we report a second case of adnexal carcinoma harboring similar morphology and an identical in frame ACTB::ZMIZ2 fusion transcript. This 2.
View Article and Find Full Text PDFExternal Validation of a 5-Factor Risk Model for Breast Cancer-Related Lymphedema.
JAMA Netw Open
January 2025
Institute of Medical Science, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Importance: Secondary lymphedema is a common, harmful side effect of breast cancer treatment. Robust risk models that are externally validated are needed to facilitate clinical translation. A published risk model used 5 accessible clinical factors to predict the development of breast cancer-related lymphedema; this model included a patient's mammographic breast density as a novel predictive factor.
View Article and Find Full Text PDFScreening of Candida auris upon admission to an intensive care unit in the United Arab Emirates.
J Infect Public Health
January 2025
Division of Medicine, Sheikh Khalifa Specialty Hospital, Ras Al Khaimah, United Arab Emirates; Environmental Safety Healthcare Provider Team, Sheikh Khalifa Specialty Hospital, Ras Al Khaimah, United Arab Emirates; Department of Family Medicine, Seoul National University Hospital, Seoul, Republic of Korea. Electronic address:
Background: Candida auris screening is one of the crucial components of infection prevention and control measures to curb the spread of C. auris. However, previous research has yielded various results on the effectiveness of C.
View Article and Find Full Text PDFIntratumoral Injection of mRNA-2752 and Pembrolizumab for High-Risk Ductal Carcinoma In Situ: A Phase 1 Nonrandomized Clinical Trial.
JAMA Oncol
January 2025
Department of Surgery, University of California, San Francisco.
Importance: Intratumoral immunotherapy that leverages the biological characteristics of high-risk ductal carcinoma in situ (DCIS) may be able to reduce the extent of surgical treatment and provide an alternative approach to improve patient outcomes.
Objective: To determine if combination intratumoral immunotherapy can activate immune cells to shrink or eliminate high-risk DCIS.
Design, Setting, And Participants: This phase 1 open-label nonrandomized clinical trial at a single academic center tested the safety and efficacy of intratumoral immunotherapy in patients with high-risk DCIS, defined as at least 2 of the following present: younger than 45 years, tumor size greater than 5 cm, high-grade, palpable mass, hormone receptor (HR)-negative, or ERBB2-positive.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!